$ARWR New JNJ1, JNJ2, JNJ3, are they possibly the 3 targets mentioned in this agreement? “Arrowhead is also eligible to receive approximately $1.9 billion in option and milestone payments for the collaboration agreement related to up to three additional targets. Arrowhead is further eligible to receive tiered royalties up to mid teens on product sales.” ir.arrowheadpharma.com/news...
  • 9
9 Likes